MRK News 54.73 10/16/2014 05:27:31 Merck & Company (MRK)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck & Company (MRK) 54.73 $MRK

BIO-Europe(R) 2014 Program is Abundant Showcase of Life Science Pharma Executives and Thought Leaders
Business Wire - 27 mins ago
BIO-Europe(R) 2014 international partnering conference will take place November 3-5 in Frankfurt, Germany, at the Portalhaus Messe Frankfurt conference center. BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
MRK: 54.73 (-1.60)

3 Small-Cap Biotech Stocks to Buy if the Market Crashes
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 1:38PM CDT
The Russell 2000  small-cap stock index is the most widely used proxy for small-cap stocks and the exchange traded fund that tracks that index  has tumbled 11.6% this year. That's a frightening drop, but it's been proven time and time again that...
JNJ: 98.21 (+1.20), INSY: 37.28 (+2.29), PTLA: 25.82 (+0.21), PFE: 28.19 (-0.27), MRK: 54.73 (-1.60), OPHT: 40.75 (+2.59), IWM: 106.60 (+1.06), BMY: 48.96 (+0.04), REGN: 334.75 (+6.68)

Cramer: The Bear’s on the Move -- and the Panic Is Palpable
at The Street - Wed Oct 15, 12:20PM CDT
After a prolonged period when it seemed that every dip was worth buying, we have run into a dip that isn't.
EMES: 75.95 (+1.09), MRK: 54.73 (-1.60), LINE: 22.40 (-0.50), GIS: 49.11 (-0.41)

Next Support Level for Merck (MRK) is $55.12
Comtex SmarTrend(R) - Wed Oct 15, 8:59AM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $56.34 today and has reached the first level of support at $55.72. Should the shares continue to fall, the support pivots of $55.12 and $53.90 will be of interest.
MRK: 54.73 (-1.60)

Johnson & Johnson and Bristol-Myers Squibb’s New Collaboration Just the Tip of the Iceberg
Brian Orelli, The Motley Fool - Motley Fool - Wed Oct 15, 7:45AM CDT
If one drug is good, two drugs must be better. That seems to be what Johnson & Johnson and Bristol-Myers Squibb are thinking with the clinical trial collaboration agreement they entered to test Johnson & Johnson's Imbruvica with...
JNJ: 98.21 (+1.20), PCYC: 108.03 (+4.24), PFE: 28.19 (-0.27), MRK: 54.73 (-1.60), BMY: 48.96 (+0.04), NVS: 86.22 (-0.65)

Merck Announces Final Results of Tender Offers for Eight Series of Notes
Business Wire - Wed Oct 15, 7:02AM CDT
Merck & Co., Inc. ("Merck" (NYSE:MRK), known as MSD outside the United States and Canada, announced today the final results of the previously announced offers to purchase (collectively, the "Offers" any and all of the outstanding notes listed in the table below (collectively, the "Notes" . On Oct. 6, 2014, Merck commenced the Offers in accordance with the terms and conditions set forth in the Offer to Purchase, dated Oct. 6, 2014 (the "Offer to Purchase" . The Offers expired at 5:00 p.m., New York City time, yesterday, on Oct. 14, 2014 (the "Expiration Time" .
MRK: 54.73 (-1.60)

Ex-financial analyst facing insider trading charge
AP - Tue Oct 14, 6:28PM CDT
NEW YORK (AP) — A former senior finance analyst at Merck & Co. is facing an insider trading charge after authorities said Tuesday that he passed secrets to a friend he met at college that earned $722,000 in illegal profits.
MRK: 54.73 (-1.60)

Merck Announces Pricing of Tender Offers for Eight Series of Notes
Business Wire - Tue Oct 14, 5:20PM CDT
Merck & Co., Inc. ("Merck" (NYSE:MRK), known as MSD outside the United States and Canada, announced today the pricing of the previously announced offers to purchase (collectively, the "Offers" any and all of the outstanding notes listed below (collectively, the "Notes" . The Offers are being made upon, and are subject to, the terms and conditions set forth in the Offer to Purchase, dated Oct. 6, 2014 ("Offer to Purchase" .
MRK: 54.73 (-1.60)

Can Dividend Stock GlaxoSmithKline plc Bounce Back?
George Budwell, The Motley Fool - Motley Fool - Tue Oct 14, 12:09PM CDT
The pharmaceutical industry has a bad rep when it comes to corruption in general and bribery in particular. For example, French drugmaker Sanofi  recently fessed up to U.S. authorities about an illegal payment scheme to doctors in East Africa and...
PFE: 28.19 (-0.27), MRK: 54.73 (-1.60), AMGN: 130.90 (-1.30), LLY: 62.87 (-0.27), GSK: 43.13 (-0.55), BMY: 48.96 (+0.04), SNY: 51.50 (-0.75), NVS: 86.22 (-0.65)

Research and Markets: Merck's Singulair (Asthma) CysLT1 Receptor Inhibitor - Forecast and Market Analysis to 2023
Business Wire - Tue Oct 14, 8:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jlpjgt/singulair) has announced the addition of the "Singulair (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
MRK: 54.73 (-1.60)

Merck's Singulair (Asthma) CysLT1 Receptor Inhibitor - Forecast and Market Analysis to 2023
M2 - Tue Oct 14, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nm4qzb/singulair) has announced the addition of the "Singulair (Asthma) - Forecast and Market Analysis to 2023" report to their offering. Singulair, developed by Merck, is a CysLT1 receptor inhibitor, blocking the physiologic actions of leukotriene D4 (LTD4). LTD4 belongs to the family of Cys-LTs, which are mediators released from a variety of cells, including mast cells and eosinophils, and which bind to the family of CysLT receptors. Several studies have determined that there are higher concentrations of Cys-LTs in the airways and urine of asthmatics compared with non-asthmatic individuals. The production of CysLTs is increased in asthmatics, particularly during the early phase of bronchoconstriction that follows allergen challenge. Cys-LT signaling results in airway edema, smooth muscle contraction, and aberrant immune cell activity. Scope - Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Singulair including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Singulair for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Singulair (montelukast) 7 Appendix For more information visit http://www.researchandmarkets.com/research/nm4qzb/singulair
MRK: 54.73 (-1.60)

Research and Markets: Merck's Dulera Asthma Treatment - Forecast and Market Analysis to 2023
Business Wire - Tue Oct 14, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xpl55r/dulera_asthma) has announced the addition of the "Dulera (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
MRK: 54.73 (-1.60)

Merck's Dulera Asthma Treatment - Forecast and Market Analysis to 2023
M2 - Tue Oct 14, 6:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2ks3p/dulera_asthma) has announced the addition of the "Dulera (Asthma) - Forecast and Market Analysis to 2023" report to their offering. Merck's Dulera is an FDC of formoterol fumarate and mometasone furoate. Mometasone furoate is a corticosteroid with potent anti-inflammatory activity. Although the precise action of corticosteroids in asthma is still unknown, their role in treating inflammation is a result of their inhibitory effects on multiple cell types and mediators involved in the asthmatic response. Mometasone furoate binds to the human glucocorticoid receptor 12 times more strongly than dexamethasone, and five times more strongly than budesonide, although how these differences in receptor affinity affect the clinical outcomes of the drug are unknown. Scope - Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Dulera including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Dulera for the top one country from 2013 to 2023. - Sales information covered for the US Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Dulera (mometasone furoate/formoterol fumarate) 7 Appendix For more information visit http://www.researchandmarkets.com/research/g2...era_asthma
MRK: 54.73 (-1.60)

Western Blotting Market Outlook 2018: Product (Instruments (Manual/Semi-automated/Automated) & Consumables (Kits/Reagents/Membrane) Analysis
M2 - Tue Oct 14, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb8c2b/western_blotting) has announced the addition of the "Western Blotting Market by Product, Consumables, by Application - End-User Analysis & Global Forecast to 2018" report to their offering. The global market was valued at $296 million in 2013 and is expected to grow at a CAGR of 4.8% from 2013 to 2018, to reach $374.2 million by 2018. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW) Western Blotting Market by Product (Instruments (Manual/Semi-automated/Automated), Consumables (Kits/Reagents/Membrane), by Application (Disease Diagnosis/Agriculture/Biomedical Research) - End-User Analysis & Global Forecast to 2018 Over the years, the western blotting market, comprising of instruments and consumables, has witnessed various technological advancements to improve the sensitivity, reproducibility, quantifiability, and speed of western blot experiments. These advancements have led to a growth in the number of applications. Western blotting instruments and consumables have its applications in disease diagnosis, agriculture, biomedical and biochemical research, biologics (therapeutics), and QC tests in the biopharmaceutical industry. Western blotting consumables have the largest share in the global western blotting market, as they have a variety of applications in all areas, which include disease diagnosis, agriculture, biomedical and biochemical research, and QC tests in the biopharmaceutical, pharmaceutical, and biotechnology industry. The biomedical and biochemical research segment accounted for the largest share of the western blotting application market, as western blotting techniques are extensively used in the area to separate, purify, and detect proteins. In the coming years, the western blotting market is expected to experience the highest growth in the Asian region, with emphasis on India and China. These countries are expected to serve as new revenue pockets for the western blotting manufacturers. The high growth in these regions can be attributed to the extensive research in the field of crop science and growing pharmaceutical and biotechnology industry in India and China. In addition, rising incidences of HIV infection in the Asian region is likely to propel the market. The U.S. and European markets are witnessing increased funding for researches that use western blotting. The major players in the global western blotting market include: - Thermo Fisher Scientific, Inc. - Bio-Rad Laboratories, Inc. - GE Healthcare - Merck Millipore - Sigma-Aldrich Corporation - PerkinElmer, Inc. - Roche Applied Science - ProteinSimple, Inc. - LI-COR Biosciences - Advansta, Inc. For more information visit http://www.researchandmarkets.com/research/zb...n_blotting
SIAL: 135.15 (-0.61), MRK: 54.73 (-1.60), PKI: 39.85 (-0.55)

North America Pharmaceutical Packaging Market - By Primary Packaging Material, Type Of Packaging, Geography And Vendors - Forecasts, Trends And Shares (2014- 2019)
PR Newswire - Mon Oct 13, 5:21PM CDT
North America is a huge market for pharmaceutical companies. In 2012, North America accounted for more than 40% of the world pharmaceutical sales. Many of the giants of the pharmaceutical industry are based out of US like Pfizer, Johnson and Johnson, Merck and Co. etc.
MRK: 54.73 (-1.60)

Merck Set to Possibly Rebound After Yesterday's Selloff of 4.30%
Comtex SmarTrend(R) - Mon Oct 13, 3:54PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $55.98 to a high of $58.55. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $58.57 on volume of 14.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 54.73 (-1.60)

SmarTrend Watching for Potential Rebound in Shares of Merck After 4.30% Loss
Comtex SmarTrend(R) - Mon Oct 13, 3:53PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $55.98 to a high of $58.55. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $58.57 on volume of 14.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 54.73 (-1.60)

IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 26.41 (+4.29), BIIB: 305.69 (+4.11), FWP: 17.50 (-1.49), KITE: 31.85 (+0.55), XENE: (), MRK: 54.73 (-1.60), CFG: 21.85 (-0.60), ZAYO: (), ATRA: (), TEVA: 50.09 (+0.19), VBAY: (), GWB: 18.00 (+0.10)

Stock Market Today: S&P Closes at 5-Month Low With No News to Break Losing Streak
at The Street - Mon Oct 13, 3:20PM CDT
Stock markets sell off into Monday's close with lingering concerns over global economic health keeping investors at bay.
NSC: 105.20 (+0.75), ATLS: 37.45 (+2.15), SFLY: 41.51 (+0.07), NGLS: 60.70 (+0.88), DIS: 82.08 (-2.06), CLF: 9.32 (+0.25), CSX: 32.98 (+0.37), INTC: 31.27 (-0.87), VALE: 11.56 (-0.24), APL: 34.61 (+0.84), BHP: 58.67 (+0.31), MRK: 54.73 (-1.60), GOOGL: 540.73 (-7.96), CP: 187.12 (-1.57)

Alnylam Drug Scores Against Rare Nerve Disease
at Investor's Business Daily - Mon Oct 13, 12:59PM CDT
Biotech Alnylam (ALNY) reported positive midstage trial results for its drug candidate patisiran Monday, sending its stock up 20% to a seven-month high on the stock market today. The phase-two trial tested patisiran in familial amyloidotic...
ALNY: 84.39 (+1.44), PFE: 28.19 (-0.27), MRK: 54.73 (-1.60), SNY: 51.50 (-0.75)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 39

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 128

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 164

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 152

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Tronox Pushes Back on Creditor Restructuring Chatter Firmly

Updated Category News Views 146

A Creditor Rumor Is Not a Restructuring Plan Two creditor groups hiring law firms can make a stock chart look like it stepped on a rake, but it is not the same thing as a debt workout. That distinction is the whole point of Tronox Holdings' November 18 update. A November 17 Wall Street Journal report said two groups of creditors had retained firms described as...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 14

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Shenzhen’s APEC Moment Puts Pacific Trade Links in Focus

Updated Category News Views 97

A city that once logged eight stock trades in a day is hosting APEC with a very different kind of ledger in view. Shenzhen Stock Exchange began trial operations on December 1, 1990 with one stock, eight trades and roughly 200,000 yuan in turnover. By the end of September 2026, it had 2,908 listed companies and about 42.43 trillion yuan in combined market value. That is...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 17

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading
DoorDash Grocery Tools Need a Hard Look Before Checkout

Updated Category News Views 30

A grocery cart built in thirty seconds can still nick your wallet all week. That is the part buried beneath the convenience pitch around DoorDash's grocery tools: planning is useful, but convenience only earns its keep when the final basket, delivery charge, substitutions, and timing actually line up. The 2026 review from Expert Consumers highlights features that are...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 55

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Join Us for Engaging Insights at the Boston IT Summit

Updated Category News Views 115

On November 7th, the Boston Cloud Connect Summit brought together industry heavyweights to tackle pressing issues in cybersecurity and artificial intelligence. With tech's rapid evolution, you know this ain't just some run-of-the-mill conference; it’s a showcase of brains tackling real threats. Cybersecurity Insights: Joe Flores at the Helm Joe Flores, Massachusetts...

Continue Reading
Revolutionizing Fitness and Entertainment: HYROX Partners with Legendz

Updated Category News Views 306

HYROX Teams Up with Legendz for Unmatched Experiences HYROX, a leader in the world of fitness racing, has announced an exciting partnership with Legendz Social Sportsbook & Casino, aiming to merge the world of competitive fitness with top-tier entertainment. This collaboration will not only uplift the profile of fitness events but also enhance fan engagement like never...

Continue Reading
DXC Technology Teams with Ferrari for Advanced Automotive HMI

Updated Category News Views 210

DXC Technology Partners with Ferrari for Next-Gen HMI Development DXC Technology (NYSE: DXC) has entered a groundbreaking partnership with Ferrari aimed at transforming the driver experience through advanced Human Machine Interface (HMI) systems in the latest automotive models. This collaboration allows DXC to leverage its extensive expertise in the automotive sector to...

Continue Reading
CEO Aman Narang's Selling Decision Raises Investor Interest

Updated Category News Views 250

Understanding the Recent Insider Sale at Toast A recent SEC filing has brought to light an important transaction involving Aman Narang, the CEO of Toast (NYSE: TOST). On a notable day, Narang sold 1,732 shares of Toast, amounting to a total value exceeding $61,000. This insider action inevitably attracts the attention of seasoned investors and market observers alike....

Continue Reading
Blue Cross and Blue Shield of Montana: Quality Health Coverage For All

Updated Category News Views 259

Blue Cross and Blue Shield of Montana Enhances Health Offerings Blue Cross and Blue Shield of Montana (BCBSMT) is dedicated to providing quality individual and family health insurance plans across Montana as the open enrollment period commences. Experience and Availability of Plans For over 85 years, BCBSMT has been a cherished provider in Montana, actively extending its...

Continue Reading
om Blog Section End -->